| Field | Specification |
|---|---|
| Target | |
| Alternative names | Ubiquitin-like modifier-activating enzyme 1;6.2.1.45 ;Protein A1S9;Ubiquitin-activating enzyme E1;UBA1;A1S9T, UBE1; |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human UBA1 |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone IAC-21 is a rabbit monoclonal antibody that recognizes ubiquitin-like modifier-activating enzyme 1 (gene UBA1) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF and flow cytometry. The predicted molecular weight is 117.8 kDa, and the supplier reports an observed band at about 118 kDa.
UBA1 is the major ubiquitin-activating (E1) enzyme that starts the ubiquitination cascade. It uses ATP to activate ubiquitin and forms a thioester with it, then passes ubiquitin to E2 conjugating enzymes, so it is required for protein degradation by the proteasome and for many signaling and DNA repair processes.
| Target | Ubiquitin-like modifier-activating enzyme 1 (gene UBA1; UniProt P22314, human) |
|---|---|
| Clone | IAC-21 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 117.8 kDa |
| Observed MW | 118 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunohistochemistry | 1:50–1:200 |
| Immunocytochemistry / Immunofluorescence | 1:50–1:200 |
| Flow cytometry | 1:20 |
Samples with a confirmed band (WB): human Jurkat cells, human SiHa cells, human 293T cells, human PC-3 cells, rat brain tissue, mouse brain tissue, mouse kidney tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:1000 overnight at 4 °C, HRP-conjugated secondary antibody at 1:500, ECL detection.
Samples with confirmed staining (IHC): human acinic cells carcinoma of parotid tissue, human clear cells renal cells carcinoma tissue, human colon adenocarcinoma tissue, human liver cancer tissue, human ovarian cancer tissue, human tonsil tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Synthetic peptide based on the sequence of human UBA1.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places ubiquitin-like modifier-activating enzyme 1 in the cytoplasm, mitochondrion, nucleus and SUBCELLULAR LOCATION:. Tissue expression noted by UniProt (human): Detected in erythrocytes (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
